Grifols, S.A. (GRFS)
$7.17-2.71%Close
SELLRECOVERY · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $6.1B
- Beta
- 1.19
- Div yield
- 1.48%
- P/E (TTM)
- 14.63
- Short % float
- 0.84%
- Days to cover
- 8.7
- SI change
- +105.0%
- 1W
- -4.65%
- 1M
- -4.14%
- vs SPY 1W
- -4.52%
- vs SPY 1M
- -6.65%
Industry peers
FMP comparable companies · ranked by market cap
- ABTSELLAbbott Laboratories$170.4BRECOVERYQ 19$98.49+0.78%
- BDXBUYBecton, Dickinson and Company$50.4BBULLQ 21$182.75-0.80%
- TECHBUYBio-Techne Corporation$11.3BBULLQ 19$72.45-0.11%
- BIOSELLBio-Rad Laboratories, Inc.$9.7BBEARQ 19$360.40-0.19%
- HAEBUYHaemonetics Corporation$5.4BBULLQ 11$119.47-0.28%
- ADMABUYADMA Biologics, Inc.$2.4BRECOVERYQ 9$10.33+1.28%
- MRVISELLMaravai LifeSciences Holdings, Inc.$2.0BCRISISQ -2$7.21-7.51%
- QDELBUYQuidelOrtho Corporation$846MRECOVERYQ 8$12.41+6.42%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on GRFS?
- LOPJLB’s latest quantitative signal on Grifols, S.A. (GRFS) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is GRFS in?
- Grifols, S.A. (GRFS) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Grifols, S.A. (GRFS) do?
- Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunogl…